What did health authorities know about serious heart problems following COVID-19 vaccination — and when did they know it?
A newly published peer-reviewed study is reopening that question with an examination of hundreds of Israeli hospitalization records from the early vaccine rollout. Its authors say the records show that Israeli health officials and Pfizer were receiving information about myocarditis and other serious medical events months before the risk became widely communicated to physicians and the public.
At the centre of the controversy are 531 hospitalization records, 67 deaths and a timeline stretching back to early 2021.
The records were contained in an Israeli Ministry of Health dataset covering March 2021 through May 2022, according to reporting by Children’s Health Defense. The authors of the EXCLI Journal study concluded that the data revealed a significant cardiac safety signal associated with Pfizer-BioNTech’s COVID-19 vaccine that was not publicly communicated for approximately three to four months.
The allegation is consequential because the timing overlaps with a period when millions of people around the world were making decisions about COVID-19 vaccination.
And the youngest patients in the dataset are drawing particular scrutiny.
Â
Help keep this independent voice alive and uncensored -> Buy us a Coffee <-
Nearly 40% of Hospitalization Records Involved People Under 30
Of the 530 hospitalization records containing valid age information, 211 — or 39.8% — involved patients younger than 30, according to the study figures cited by The Defender.
Myocarditis or pericarditis appeared in 250 of the 531 hospitalization records, representing 47.1%.
Among patients under 30, that proportion was considerably higher: 151 of 211 records, or 71.6%, involved myocarditis or pericarditis.
The records also included 48 patients younger than 18 diagnosed with myocarditis or pericarditis.
Another detail stands out.
Of the 211 patients under 30, the study reported that 134 had no meaningful medical history. Ninety-nine of those patients were diagnosed with myocarditis or pericarditis, and 90 of those 99 were male.
The study authors also reported that a significant number of younger patients experienced acute cardiac inflammation within days to weeks after vaccination.
Those temporal associations are important safety signals, although timing alone does not prove that vaccination caused every individual hospitalization or death contained in the dataset.
Two Deaths Under 50 Were Attributed to Myocarditis
The dataset contained 67 deaths overall, including nine involving people younger than 50.
According to the study, two of those nine deaths were attributed to myocarditis: a 22-year-old woman and a 47-year-old man.
Another record involved a 35-year-old man whose condition was described as worsening heart failure, although myocarditis was not recorded in that case.
Myocarditis is inflammation of the heart muscle and can, in serious cases, lead to complications including abnormal heart rhythms and death.
But the researchers weren’t looking only at myocarditis.
Their review identified records involving a wider collection of serious medical events, including arrhythmias, heart failure, stroke, seizures, encephalitis, Guillain-Barré syndrome, suspected anaphylaxis, acute kidney injury and sudden hearing loss.
The presence of an event in a post-vaccination safety dataset, however, is not by itself proof that the vaccine caused it. Establishing causation requires additional clinical and epidemiological evidence.
The study’s central argument concerns something different: whether the pattern in the reports constituted a safety signal that should have been communicated sooner.
Pfizer Was Receiving Reports by March 2021, Study Says
The timeline is where the story becomes particularly significant.
According to the study, Pfizer received reports concerning the hospitalizations and deaths between March 2021 and May 2022.
The first report cited by the researchers was dated March 25, 2021.
It contained information concerning 157 hospitalizations and 46 deaths.
The researchers said reports sent to Pfizer included a notable proportion of younger people, including patients with no meaningful previous medical history.
Yet public warnings about myocarditis did not immediately follow.
The article reports that early myocarditis cases had already been detected in Israel by January 2021, shortly after the Pfizer-BioNTech vaccine rollout began.
On February 28, 2021, Israeli officials alerted the U.S. Centers for Disease Control and Prevention and other health authorities about approximately 40 myocarditis cases, according to material cited in the report.
In early March, the CDC was reportedly warned about large numbers of myocarditis and pericarditis cases involving young people in Israel.
Yet on April 26, the CDC and U.S. Food and Drug Administration publicly said they had not identified a myocarditis safety signal.
It wasn’t until May 28, 2021 that the CDC recommended that clinicians report all cases of myocarditis and pericarditis.
The study authors argue that the delay may have affected clinical awareness and people’s ability to make fully informed decisions.
That is one of the most serious questions raised by the research.
The Dataset Itself Raises More Questions
There is another layer to the story.
The researchers said the Israeli Ministry of Health dataset appears to have undergone multiple revisions.
According to the study, later versions added clinical information, changed diagnoses and reporting dates and omitted some records.
One death appearing in an October 2021 version reportedly disappeared from the December version and subsequent datasets.
The researchers said they could find no formal audit trail explaining who made the changes or why.
That doesn’t establish that records were deliberately concealed. But without methodological documentation explaining the revisions, the researchers said they could not determine the reasons for the changes.
That uncertainty matters.
Safety surveillance depends not merely on collecting reports but on maintaining transparent records showing how data were classified, updated and evaluated.
When records change without an accessible audit trail, questions inevitably follow.
Critics Say Informed Consent Was at Stake
Several experts quoted by The Defender argue that the implications extend beyond statistical surveillance.
Epidemiologist M. Nathaniel Mead said age- and sex-specific warnings should have been provided early enough for people — particularly young men — to consider delaying another dose or making a different decision.
Children’s Health Defense senior research scientist Karl Jablonowski questioned why the myocarditis deaths described in the Israeli records were not found in the U.S. Vaccine Adverse Event Reporting System, or VAERS.
Steve Kirsch of the Vaccine Safety Research Foundation went further, accusing Israeli authorities of prioritizing manufacturers over the public.
Dr. Jane Orient of the Association of American Physicians and Surgeons argued that similar failures occurred internationally and called for mRNA vaccines to be withdrawn.
Those are the views of the individuals quoted in the source and should be distinguished from the underlying dataset itself.
The data can establish what was recorded.
The researchers can analyze what those records appear to show.
But accusations about why officials acted as they did require a different level of evidence.
The Central Question Isn’t Going Away
More than five years after the initial COVID-19 vaccination campaign, the argument over vaccine safety has moved into a new phase.
It is no longer only about whether myocarditis can occur following vaccination.
The controversy raised by this study is about timing, transparency and disclosure.
When was the signal strong enough that physicians should have been warned?
When should the public have been told?
What information did Pfizer possess at each stage?
Why were versions of the Israeli dataset changed?
And could earlier disclosure have changed vaccination decisions for younger people at elevated risk?
The study’s authors believe the delay had consequences for clinical awareness and informed decision-making.
Their findings do not establish that every serious medical event in the dataset was caused by vaccination, nor do they resolve every question surrounding the revisions to the government records.
But they put the timeline back under scrutiny.
And in a public-health system that ultimately depends on trust, when officials disclose a potential risk can matter almost as much as what they eventually disclose.
About the Author
